## (19) World Intellectual Property Organization International Bureau





## (43) International Publication Date 16 January 2003 (16.01.2003)

#### **PCT**

# (10) International Publication Number WO 03/004643 A3

(51) International Patent Classification7:

....

C12N 15/10

- (21) International Application Number: PCT/EP02/07419
- (22) International Filing Date: 2 July 2002 (02.07.2002)
- (25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

01202569.8

3 July 2001 (03.07.2001) E

- (71) Applicant (for all designated States except US):
  VLAAMS INTERUNIVERSITAIR INSTITUUT
  VOOR BIOTECHNOLOGIE VZW [BE/BE]; Rijvisschestraat 120, B-9052 Zwijnaarde (BE).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): EYCKERMAN, Sven [BE/BE]; Citadellaan 75, B-9000 Gent (BE). TAV-ERNIER, Jan [BE/BE]; Bottelweg 2, B-9860 Balegem (BE). VANDEKERCKHOVE, Joël [BE/BE]; Rode Beukendreef 27, B-8210 Loppem (BE).


- (74) Common Representative: VLAAMS INTERUNIVER-SITAIR INSTITUUT VOOR BIOTECHNOLOGIE VZW; Rijvisschestraat 120, B-9052 Zwijnaarde (BE).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PI, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM. ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR), OΛΡΙ patent (BF, BJ, CF, CG, CI, CM, GΛ, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

#### Published:

··· with international search report

[Continued on next page]

(54) Title: REVERSED MAMMALIAN PROTEIN-PROTEIN INTERACTION TRAP



(57) Abstract: The present invention relates to a recombinant receptor, comprising a ligand-binding domain and a signaling domain that comprises a heterologous bait polypeptide, which receptor is inactivated by binding of a prey polypeptide to said heterologous bait peptide, either in presence or absence of a ligand binding to said ligand-binding domain. The receptor is activated by addition of a compound that disrupts the bait-prey interaction. The present invention also relates to a method to screen compounds that disrupt compound-compound-binding using said recombinant receptor.

03/004643 A3



(88) Date of publication of the international search report: 27 March 2003

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

Ir Ional Application No
PCT/EP 02/07419

A CLASSIF	FICATION OF SUBJECT MATTER C12N15/10	•						
According to	International Patent Classification (IPC) or to both national classificati	on and IPC						
B. FIELDS	SEARCHED							
IPC 7	cumentation searched (classification system followed by classification C12N	symbols)						
	ion searched other than minimum documentation to the extent that su							
Electronic da	ata base consulted during the International search (name of data base	and, where practical, search terms used)						
EPO-Internal, WPI Data, PAJ, MEDLINE, BIOSIS, EMBASE								
C. DOCUME	ENTS CONSIDERED TO BE RELEVANT							
Category •	Citation of document, with indication, where appropriate, of the rele	vant passages	Relevant to claim No.					
χ	WO 97 31113 A (RICKLES RICHARD J PHARMA INC (US)) 28 August 1997 (1997-08-28) the whole document	;ARIAD	1-21					
X	FASHENA S J ET AL: "The continue evolution of two-hybrid screening approaches in yeast: how to outwidifferent preys with different ba GENE, ELSEVIER BIOMEDICAL PRESS. AMSTERDAM, NL, vol. 250, no. 1-2, May 2000 (2000 pages 1-14, XP004201578 ISSN: 0378-1119 abstract; figures 1-3	t 1ts"	1-21					
X Furt	.I	X Patent family members are listed	In annex.					
* Special ca	ategories of cited documents:	Te later document nublished after the Inte	ernational filing date					
'A' document defining the general state of the art which is not considered to be of particular relevance  'E' earlier document but published on or after the international  'T' later document published after the international filing date or priority date and not in conflict with the application but determined to the or priority date and not in conflict with the application but determined to the or priority date and not in conflict with the application but determined to the or priority date and not in conflict with the application but determined to the or priority date and not in conflict with the application but determined to the or priority date and not in conflict with the application but determined to the or priority date and not in conflict with the application but determined to the or priority date and not in conflict with the application but determined to the or priority date and not in conflict with the application but determined to the or priority date and not in conflict with the application but determined to the or priority date and not in conflict with the application but determined to the or priority date and not in conflict with the application but determined to the or priority date and not in conflict with the application but determined to the or priority date and not in conflict with the application but determined to the or priority date and not in conflict with the application but determined to the or priority date and not in conflict with the application but determined to the or priority date and not in conflict with the application but determined to the or priority date and not in conflict with the application but determined to the or priority date and not in conflict with the application but determined to the or priority date and not in conflict with the application or priority date and not in conflict with the application but determined to the or priority date and not in conflict with the application or priority date and not in conflict with the application or priority date and not in conflic								
) which	ent which may throw doubts on priority claim(s) or	cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone of document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the						
other	nent referring to an oral disclosure, use, exhibition or means ent published prior to the international filing date but	document is combined with one or ments, such combination being obvious in the art.  *&* document member of the same patent	ore other such docu— us to a person skilled					
	than the priority date claimed  actual completion of the international search	Date of mailing of the international se						
	December 2002	20/12/2002						
Name and	mailing address of the ISA	Authorized officer						
	European Patent Office, P.B. 5818 Patentlaan 2 NL – 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Novak, S						

Int Ional Application No PCT/EP 02/07419

		PC1/EP 02/0/419
C.(Continua	ation) DOCUMENTS CONSIDERED TO BE RELEVANT	Indianate days to
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
х	EYCKERMAN S ET AL: "Identification of the Y985 and Y1077 motifs as SOCS3 recruitment sites in the murine leptin receptor." FEBS LETTERS, vol. 486, no. 1, 2000, pages 33-37, XP001026110 ISSN: 0014-5793 the whole document	1-21
Y	OSBORNE M A ET AL: "THE YEAST TRIBRID SYSTEM - GENETIC DETECTION OF TRANS-PHOSPHORYLATED ITAM-SH2-INTERACTIONS" BIO/TECHNOLOGY, NATURE PUBLISHING CO. NEW YORK, US, vol. 13, 1 December 1995 (1995-12-01), pages 1474-1478, XP002033515 ISSN: 0733-222X abstract; figures 1,2; tables 1,2	1-21
Υ	FR 2 782 084 A (CENTRE NAT RECH SCIENT) 11 February 2000 (2000-02-11) the whole document	1-21
Y	WO 00 46406 A (ALPHAGENE INC ;HOFFMANN HEIDI (US); RAPEIJKO PETER (US); HIGGINS K) 10 August 2000 (2000-08-10) abstract	1-21
Υ	US 5 525 490 A (POWERS SCOTT ET AL) 11 June 1996 (1996-06-11) the whole document	1-21
Υ	LI CAI ET AL: "Leptin receptor activation of SH2 domain containing protein tyrosine phosphatase 2 modulates Ob receptor signal transduction."  PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 96, no. 17, 17 August 1999 (1999-08-17), pages 9677-9682, XP002185670  Aug. 17, 1999 ISSN: 0027-8424 abstract; figures 1-5	1-21
A	WO 00 07014 A (VANDEKERCKHOVE JOEL STEFAAN; VLAAMS INTERUNIV INST BIOTECH (BE); T) 10 February 2000 (2000-02-10)	
<b>A</b>	EP 1 088 892 A (VLAAMS INTERUNIVERSITAIR INST) 4 April 2001 (2001-04-04)	

ernational application No. PCT/EP 02/07419

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)
This international Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
1. Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
2. X Claims Nos.: 1-21 (part1ally) because they relate to parts of the international Application that do not comply with the prescribed requirements to such an extent that no meaningful international Search can be carried out, specifically:  see FURTHER INFORMATION sheet PCT/ISA/210
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box II Observations where unity of Invention Is lacking (Continuation of Item 2 of first sheet)
This International Searching Authority found multiple inventions in this international application, as follows:
As all required additional search fees were timely paid by the applicant, this international Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:  .
4. No required additional search fees were timely paid by the applicant. Consequently, this international Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
Remark on Protest  The additional search fees were accompanied by the applicant's protest.  No protest accompanied the payment of additional search fees.

#### FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 1-21 (partially)

Present claims 1-21 relate to an extremely large number of possible recombinant receptors, and methods utilizing such polypeptides. In fact, the claims contain so many options, variables, possible permutations and provisos that a lack of clarity (and/or conciseness) within the meaning of Article 6 PCT arises to such an extent as to render a meaningful search of the claims impossible. Consequently, the search has been carried out for those parts of the application which do appear to be clear (and/or concise), namely claims 1-21 inasfar the claimed molecules relate to those exemplified in the application.

Additionally, present claims 1-21 relate to recombinant receptors, and methods utilizing such polypeptides defined by reference to a desirable characteristic or property, namely that the activation of the claimed polypeptides can be inhibited by binding of a prey polypeptide to a bait peptide.

The claims cover all receptors having this characteristic or property, whereas the application provides support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT for only a very limited number of such receptors and methods.

In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Independent of the above reasoning, the claims also lack clarity (Article 6 PCT). An attempt is made to define the recombinant proteins by reference to a result to be achieved. Again, this lack of clarity in the present case is such as to render a meaningful search over the whole of the claimed scope impossible. Consequently, the search has been carried out for those parts of the claims which appear to be clear, supported and disclosed, namely those parts relating to the molecules and methods exemplified in the application.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

information on patent family members

Int Itonal Application No PCT/EP 02/07419

				PUITE	02/0/419
Patent document cited in search report		Publication date		Patent family member(s)	Publication date
WO 9731113	A	28-08-1997	AU CA EP JP WO US	2053197 A 2246300 A1 0882128 A1 2000506007 T 9731113 A1 6303319 B1	10-09-1997 28-08-1997 09-12-1998 23-05-2000 28-08-1997 16-10-2001
FR 2782084	A	11-02-2000	FR CA EP WO	2782084 A1 2339083 A1 1102843 A1 0008148 A1	11-02-2000 17-02-2000 30-05-2001 17-02-2000
WO 0046406	Α	10-08-2000	AU WO US	3223100 A 0046406 A2 2002019006 A1	25-08-2000 10-08-2000 14-02-2002
US 5525490	A	11-06-1996	AU WO	2779095 A 9526400 A1	17-10-1995 05-10-1995
WO 0007014	A	10-02-2000	AU CA WO EP JP	5508499 A 2335107 A1 0007014 A2 1101112 A2 2002521496 T	21-02-2000 10-02-2000 10-02-2000 23-05-2001 16-07-2002
EP 1088892	A	04-04-2001	EP AU WO EP US	1088892 A1 7780300 A 0121817 A1 1214430 A1 6479280 B1	04-04-2001 24-04-2001 29-03-2001 19-06-2002 12-11-2002